The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Inflammatory Bowel Disease (IBD) Treatment-Global Market Insights and Sales Trends 2025
Synopsis
Inflammatory bowel disease is a group of medical indication that causes chronic inflammation in the gastrointestinal tract. The inflammatory bowel disease mainly comprises of Ulcerative colitis and Crohn’s disease. The ulcerative colitis primarily affects the large intestine and anus and it causes the inflammation sores in the inner lining of colon and rectum. The Crohn’s disease affects any part of gastrointestinal tract and unlike ulcerative colitis, it affects all the layers of gastrointestinal walls. The ulcerative colitis is more prevalent than that of Crohn’s disease. The IBD affects equally in men and women and has prevalence and incidence rates in developed countries than that of developing and under developed countries. The exact cause of inflammatory bowel disease are not well understood however, the combination of several factors such as autoimmune disorders, genetic factors, lifestyle related risks factors such as smoking, sedentary lifestyle, lack of exercise are likely to contribute to the development of symptoms of inflammatory bowel disease. The common symptoms of inflammatory bowel disease includes the severe abdominal cramps and pain, persistent diarrhea, occasional rectal bleeding.
The global Inflammatory Bowel Disease (IBD) Treatment market size is expected to reach US$ 15660 million by 2029, growing at a CAGR of 2.3% from 2023 to 2029. The market is mainly driven by the significant applications of Inflammatory Bowel Disease (IBD) Treatment in various end use industries. The expanding demands from the Hospital Pharmacy, Retail Pharmacy and Online Pharmacy,, are propelling Inflammatory Bowel Disease (IBD) Treatment market. TNF Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Aminosalicyclates segment is estimated at % CAGR for the next seven-year period.
The IBD has no permanent cure and requires the lifelong disease management and treatment. Several medications such as corticosteroids, aminosalicyclates, immunomodulators, and biologic drugs such as TNF inhibitors and up to certain extent antibiotic drugs are prescribed to relive the symptoms of these diseases.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Inflammatory Bowel Disease (IBD) Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Inflammatory Bowel Disease (IBD) Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Inflammatory Bowel Disease (IBD) Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Inflammatory Bowel Disease (IBD) Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Inflammatory Bowel Disease (IBD) Treatment covered in this report include AbbVie, Pfizer, Takeda, Janssen Biotech, Allergan, Bausch Health, Takeda Pharmaceutical, Novartis and Biogen, etc.
The global Inflammatory Bowel Disease (IBD) Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AbbVie
Pfizer
Takeda
Janssen Biotech
Allergan
Bausch Health
Takeda Pharmaceutical
Novartis
Biogen
Global Inflammatory Bowel Disease (IBD) Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Inflammatory Bowel Disease (IBD) Treatment market, Segment by Type:
TNF Inhibitors
Aminosalicyclates
Immunomodulators
Corticosteroids
Global Inflammatory Bowel Disease (IBD) Treatment market, by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Inflammatory Bowel Disease (IBD) Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Inflammatory bowel disease is a group of medical indication that causes chronic inflammation in the gastrointestinal tract. The inflammatory bowel disease mainly comprises of Ulcerative colitis and Crohn’s disease. The ulcerative colitis primarily affects the large intestine and anus and it causes the inflammation sores in the inner lining of colon and rectum. The Crohn’s disease affects any part of gastrointestinal tract and unlike ulcerative colitis, it affects all the layers of gastrointestinal walls. The ulcerative colitis is more prevalent than that of Crohn’s disease. The IBD affects equally in men and women and has prevalence and incidence rates in developed countries than that of developing and under developed countries. The exact cause of inflammatory bowel disease are not well understood however, the combination of several factors such as autoimmune disorders, genetic factors, lifestyle related risks factors such as smoking, sedentary lifestyle, lack of exercise are likely to contribute to the development of symptoms of inflammatory bowel disease. The common symptoms of inflammatory bowel disease includes the severe abdominal cramps and pain, persistent diarrhea, occasional rectal bleeding.
The global Inflammatory Bowel Disease (IBD) Treatment market size is expected to reach US$ 15660 million by 2029, growing at a CAGR of 2.3% from 2023 to 2029. The market is mainly driven by the significant applications of Inflammatory Bowel Disease (IBD) Treatment in various end use industries. The expanding demands from the Hospital Pharmacy, Retail Pharmacy and Online Pharmacy,, are propelling Inflammatory Bowel Disease (IBD) Treatment market. TNF Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Aminosalicyclates segment is estimated at % CAGR for the next seven-year period.
The IBD has no permanent cure and requires the lifelong disease management and treatment. Several medications such as corticosteroids, aminosalicyclates, immunomodulators, and biologic drugs such as TNF inhibitors and up to certain extent antibiotic drugs are prescribed to relive the symptoms of these diseases.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Inflammatory Bowel Disease (IBD) Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Inflammatory Bowel Disease (IBD) Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Inflammatory Bowel Disease (IBD) Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Inflammatory Bowel Disease (IBD) Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Inflammatory Bowel Disease (IBD) Treatment covered in this report include AbbVie, Pfizer, Takeda, Janssen Biotech, Allergan, Bausch Health, Takeda Pharmaceutical, Novartis and Biogen, etc.
The global Inflammatory Bowel Disease (IBD) Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AbbVie
Pfizer
Takeda
Janssen Biotech
Allergan
Bausch Health
Takeda Pharmaceutical
Novartis
Biogen
Global Inflammatory Bowel Disease (IBD) Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Inflammatory Bowel Disease (IBD) Treatment market, Segment by Type:
TNF Inhibitors
Aminosalicyclates
Immunomodulators
Corticosteroids
Global Inflammatory Bowel Disease (IBD) Treatment market, by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Inflammatory Bowel Disease (IBD) Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Inflammatory Bowel Disease (IBD) Treatment
1.1 Inflammatory Bowel Disease (IBD) Treatment Market Overview
1.1.1 Inflammatory Bowel Disease (IBD) Treatment Product Scope
1.1.2 Inflammatory Bowel Disease (IBD) Treatment Market Status and Outlook
1.2 Global Inflammatory Bowel Disease (IBD) Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Inflammatory Bowel Disease (IBD) Treatment Market Size by Region (2018-2029)
1.4 Global Inflammatory Bowel Disease (IBD) Treatment Historic Market Size by Region (2018-2023)
1.5 Global Inflammatory Bowel Disease (IBD) Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Inflammatory Bowel Disease (IBD) Treatment Market Size (2018-2029)
1.6.1 North America Inflammatory Bowel Disease (IBD) Treatment Market Size (2018-2029)
1.6.2 Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (2018-2029)
1.6.4 Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (2018-2029)
2 Inflammatory Bowel Disease (IBD) Treatment Market by Type
2.1 Introduction
2.1.1 TNF Inhibitors
2.1.2 Aminosalicyclates
2.1.3 Immunomodulators
2.1.4 Corticosteroids
2.2 Global Inflammatory Bowel Disease (IBD) Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Inflammatory Bowel Disease (IBD) Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Inflammatory Bowel Disease (IBD) Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Inflammatory Bowel Disease (IBD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Inflammatory Bowel Disease (IBD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Inflammatory Bowel Disease (IBD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Inflammatory Bowel Disease (IBD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Inflammatory Bowel Disease (IBD) Treatment Revenue Breakdown by Type (2018-2029)
3 Inflammatory Bowel Disease (IBD) Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacy
3.1.2 Retail Pharmacy
3.1.3 Online Pharmacy
3.2 Global Inflammatory Bowel Disease (IBD) Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Inflammatory Bowel Disease (IBD) Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Inflammatory Bowel Disease (IBD) Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Inflammatory Bowel Disease (IBD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Inflammatory Bowel Disease (IBD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Inflammatory Bowel Disease (IBD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Inflammatory Bowel Disease (IBD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Inflammatory Bowel Disease (IBD) Treatment Revenue Breakdown by Application (2018-2029)
4 Inflammatory Bowel Disease (IBD) Treatment Competition Analysis by Players
4.1 Global Inflammatory Bowel Disease (IBD) Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Inflammatory Bowel Disease (IBD) Treatment as of 2022)
4.3 Date of Key Players Enter into Inflammatory Bowel Disease (IBD) Treatment Market
4.4 Global Top Players Inflammatory Bowel Disease (IBD) Treatment Headquarters and Area Served
4.5 Key Players Inflammatory Bowel Disease (IBD) Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Inflammatory Bowel Disease (IBD) Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AbbVie
5.1.1 AbbVie Profile
5.1.2 AbbVie Main Business
5.1.3 AbbVie Inflammatory Bowel Disease (IBD) Treatment Products, Services and Solutions
5.1.4 AbbVie Inflammatory Bowel Disease (IBD) Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 AbbVie Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer Inflammatory Bowel Disease (IBD) Treatment Products, Services and Solutions
5.2.4 Pfizer Inflammatory Bowel Disease (IBD) Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Recent Developments
5.3 Takeda
5.3.1 Takeda Profile
5.3.2 Takeda Main Business
5.3.3 Takeda Inflammatory Bowel Disease (IBD) Treatment Products, Services and Solutions
5.3.4 Takeda Inflammatory Bowel Disease (IBD) Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Janssen Biotech Recent Developments
5.4 Janssen Biotech
5.4.1 Janssen Biotech Profile
5.4.2 Janssen Biotech Main Business
5.4.3 Janssen Biotech Inflammatory Bowel Disease (IBD) Treatment Products, Services and Solutions
5.4.4 Janssen Biotech Inflammatory Bowel Disease (IBD) Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Janssen Biotech Recent Developments
5.5 Allergan
5.5.1 Allergan Profile
5.5.2 Allergan Main Business
5.5.3 Allergan Inflammatory Bowel Disease (IBD) Treatment Products, Services and Solutions
5.5.4 Allergan Inflammatory Bowel Disease (IBD) Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Allergan Recent Developments
5.6 Bausch Health
5.6.1 Bausch Health Profile
5.6.2 Bausch Health Main Business
5.6.3 Bausch Health Inflammatory Bowel Disease (IBD) Treatment Products, Services and Solutions
5.6.4 Bausch Health Inflammatory Bowel Disease (IBD) Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Bausch Health Recent Developments
5.7 Takeda Pharmaceutical
5.7.1 Takeda Pharmaceutical Profile
5.7.2 Takeda Pharmaceutical Main Business
5.7.3 Takeda Pharmaceutical Inflammatory Bowel Disease (IBD) Treatment Products, Services and Solutions
5.7.4 Takeda Pharmaceutical Inflammatory Bowel Disease (IBD) Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Takeda Pharmaceutical Recent Developments
5.8 Novartis
5.8.1 Novartis Profile
5.8.2 Novartis Main Business
5.8.3 Novartis Inflammatory Bowel Disease (IBD) Treatment Products, Services and Solutions
5.8.4 Novartis Inflammatory Bowel Disease (IBD) Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Novartis Recent Developments
5.9 Biogen
5.9.1 Biogen Profile
5.9.2 Biogen Main Business
5.9.3 Biogen Inflammatory Bowel Disease (IBD) Treatment Products, Services and Solutions
5.9.4 Biogen Inflammatory Bowel Disease (IBD) Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Biogen Recent Developments
6 North America
6.1 North America Inflammatory Bowel Disease (IBD) Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Inflammatory Bowel Disease (IBD) Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Inflammatory Bowel Disease (IBD) Treatment Market Dynamics
11.1 Inflammatory Bowel Disease (IBD) Treatment Industry Trends
11.2 Inflammatory Bowel Disease (IBD) Treatment Market Drivers
11.3 Inflammatory Bowel Disease (IBD) Treatment Market Challenges
11.4 Inflammatory Bowel Disease (IBD) Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
